Drug Discovery Services Market Size to Surpass USD 75.68 Bn by 2032
The global drug discovery services market size was estimated at USD 19.37 billion in 2022 and is expected to surpass around USD 75.68 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 14.6% during the forecast period 2023 to 2032.
Key Takeaways:
Increasing research and development investments made by pharmaceutical and biopharmaceutical companies, growing R&D pipeline for pharmaceutical drugs influencing the growth in demand for outsourcing the analytical testing services, global initiatives made for research on rare disease and orphan drugs, and maximized cost of in-house development of drugs are driving the growth for market. Also, technological advancements, the introduction of new drug discovery techniques, the expiry of patents, and rising demand for specialized testing services among end users are expected to offer growth opportunities to players in this market. However stringent regulation concerning animal use for drug discovery and the shortage of skilled professionals prove to be an restraint and challenge for drug discovery service providers.
Global Drug Discovery Services Market Report Scope
| Report Attribute | Details |
| Market Size in 2023 | USD 22.2 Billion |
| Market Size by 2032 | USD 75.68 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 14.6% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Process, Type, Drug Type, Therapeutic Area, End user |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Abbott Laboratories Inc., Advinus Therapeutics, Agilent Technologies Ubiquigent, Albany Molecular Research Inc., AstraZeneca PLC, Aurigene, Bayer AG, Charles River Laboratories International, ChemBridge Corporation, Covance |
Drug Discovery Services Market Dynamics
DRIVER: Growing R&D Expenditure in Pharma-Biotech Sector
Drug discovery and development have seen significant growth over the last decade in terms of clinical studies and the introduction of novel drug molecules. As per ClinicalTrials.gov, the number of registered studies went up from 32,517 in 2019 to 36,770 in 2022, at a CAGR of 4.2%. Companies operating in the Pharmaceutical and biopharmaceutical industry invest laboriously in developing novel drugs. Biopharmaceutical companies spend resources for research and development to deliver high-quality and innovative products to gain market capital. After studying the recent industry trends, it was observed that the leading pharma companies are increasing their R&D capabilities through significant R&D investments to see capital returns in long term and through collaborative R&D efforts. In a recent study published by Evaluate Pharma, the worldwide pharmaceutical R&D spending was valued at USD 144 billion in 2014, and this figure is estimated to reach USD 285 billion by 2028.
The growing R&D spending by pharmaceutical and biopharmaceutical companies is encouraging them to go for fully integrated or functional outsourcing services for drug discovery and development, from the early development stage to the late-stage development phase. The pharmaceutical companies have budget constraints and need to contain fixed costs, hence outsourcing has evolved as a strategic alternative to overcome the lack of in-house resources required for new product development. Major pharma companies are transitioning to a leaner business model that is dependent heavily on outsourcing. Many pharmaceutical and biopharmaceutical companies prefer to outsource their testing functions during R&D to improve profitability, meet the timelines involved in drug development, and save costs. This can be confirmed from the recent agreements by major pharmaceutical companies with CROs providing drug discovery and development services. Thus, increasing pharmaceutical R&D expenditure supports the growth of the market.
RESTRAINT: Stringent regulations governing drug discovery and animal usage
The major focus of regulatory authorities during drug approval is securing safety and efficacy. Even if these approaches confirm the quality of the products launched in the market, they significantly increase the cost of drug development process of the final product. For regions with price-sensitive emerging markets, this factor can significantly impact the uptake of a particular drug. Aside from this, multiple legislations that ensure the quality of the product (such as GMP and GLP) usually increases the manufacturing costs.
Also, there are strict guidelines govern the usage of animals in drug discovery. Mice, rats, fish, amphibians, and reptiles are the most used animals in any research. Scrutiny regarding the ethical use of animals in research has pushed governments to introduce legislation for animal safety and use, which presents several challenges to the smooth functioning of drug discovery research, and this has reinforced companies to implement other techniques to minimize animal use. For example, Novo Nordisk uses biosimulation, which uses computer models to simulate human biology. However, this has not been fully adopted across the industry.
Computer modeling is another new technology used to predict drug metabolism. However, this computer modeling technique, in silico, is still gaining support and remains in the early phase of industry adoption. It is being tested and is not expected to surpass animal testing during the forecast period fully. The viability of these AI models compared to animal models is being studied; hence, while animal usage concerns may be bypassed in the future, they are expected to restrain the market over the forecast period.
OPPORTUNITY: Technological advancements and new drug discovery techniques
Technological innovations play a significant role in increasing the efficiency and time-to-market for new drugs that are being discovered. Larger CROs have been at the forefront of this innovation. Some prominent solutions have been listed below:
Such advancements in technology will significantly drive the market for drug discovery services.
CHALLENGE: Shortage of Skilled Personnel
The pharmaceutical and biopharmaceutical industry is constantly evolving at a fast pace and professionals need to keep pace with the dynamic changes in the pharmaceutical R&D technologies and methodologies, provide quality services, and comply with good laboratory practices. The drug discovery service providers face problems in gaining and retaining well trained and skilled professionals as they compete with pharmaceutical and biotechnology companies and academic and research institutions for qualified and experienced scientists.
To compete efficiently, companies have to offer higher compensations and other benefits; this may affect the finances and results of operations of players, especially small-scale analytical testing providers. Thus, shortage of skilled professionals may hamper the adoption of new technologies and methodologies and inhibit the growth of the market in the coming years.
Drug Discovery Services Market Ecosystem
The market ecosystem comprises raw material suppliers, drug discovery service providers, and end users such as pharmaceutical & biotech companies, academic institutes, small CROS, and clinical laboratories. Raw material suppliers and service providers offer various supplies and services, such as instruments, consumables, assays, kits, and accessories for drug discovery studies such as PK/PD, ADME, DMPK, and other studies. CROs partner with their clients to create a trial design, implementation, and management strategy. This long-term relationship enables the partners to conduct trials successfully and bring new products into the market. Over time, the volume of work contracted out can be expanded, depending on how comfortable both partners are about taking the partnership forward.
Based on type, Chemistry Services segment accounted for the largest market share of the drug discovery services industry
Based on type, the drug discovery services market is segmented into chemistry services and biology services. The chemistry services segment commanded the largest share of this market in 2022. Growth in this market segment is largely due to the widespread application of chemistry services in various early drug development phases to deliver robust drug candidates. The extensive chemistry usage in academics, biotechnology companies, and large pharmaceutical companies also supports market growth. Biology services are expected to grow at a slower rate over the forecast period.
Based on drug type, small molecule drugs segment accounted for the largest market share of the drug discovery services industry
Based on drug type, the drug discovery services market is segmented into small-molecule drugs and biologics based on drug type. Small-molecule drugs commanded the largest share of the market in 2022. The large share of this segment can be attributed to the ease of working with small molecules, their low cost, and the increasing number of start-ups and new entrants focusing on developing small-molecule drugs.
Based on therapeutic area, oncology segment accounted for the largest market share of the drug discovery services industry
Based on the therapeutic area, the drug discovery services market is broadly segmented into oncology, infectious diseases, neurological diseases, immunological diseases, endocrine and metabolic diseases, respiratory diseases, digestive system diseases, cardiovascular diseases, genitourinary diseases and women’s health, and other therapeutic areas. Oncology is the largest segment in this market owing to the high incidence of cancer, a growing number of research studies on cancer therapeutics, and the focus on bringing innovative cancer drugs into the market.
The North American market is projected to contribute the largest share for the drug discovery services industry.
The global drug discovery services market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for drug discovery services, with an estimated share in 2022, while Europe is the second-largest market. A well-established pharmaceutical industry, ongoing R&D studies, high R&D expenditure, growth in the biosimilars and generics markets, and the rising outsourcing of R&D services by pharmaceutical and biopharmaceutical companies in the region are driving the market growth. North America is the largest pharmaceutical market in the world, with many global pharmaceutical and biopharmaceutical giants headquartered in the region, such as Laboratory Corporation of America Holdings (US), Charles River Laboratories International, Inc. (US), Thermo Fisher Scientific (US), Frontage Holdings (US), Pfizer, Inc. (US), AbbVie, Inc. (US), Abbott Laboratories (US), and Johnson & Johnson (US). These companies outsource their drug discovery and drug development services to reduce the cost and time of drug development. This is indicative of the growth opportunities in the North American market.
The drug discovery services market is dominated by a few globally established players such as Laboratory Corporation of America Holdings (US), Charles River Laboratories International Inc. (US), WuXi AppTec (China), and Thermo Fisher Scientific Inc (US), among others, are the key service providers that provided drug discovery services in last few years. Major focus was given to the deals, expansions, and new service launches due to the changing requirements of pharmaceutical and biopharmaceutical companies, academic and research institutes, and other end users across the world.
Recent Developments of Drug Discovery Services Industry
Some of the prominent players in the Global Drug Discovery Services Market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2020 to 2032. For this study, Nova one advisor, Inc. has segmented the Global Drug Discovery Services market.
By Process
By Type
By Drug Type
By Therapeutic Area
By End user
By Region
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 30)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 COVID-19 SPECIFIC ASSUMPTIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 42)
4 PREMIUM INSIGHTS (Page No. - 46)
4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW
4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE AND COUNTRY (2022)
4.3 DRUG DISCOVERY SERVICES MARKET SHARE, BY TYPE (2022)
4.4 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021 VS. 2030 (USD MILLION)
4.5 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW (Page No. - 50)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing R&D expenditure in the pharma & biopharma industry
5.2.1.2 Increasing demand for outsourcing analytical testing
5.2.1.3 Initiatives for research on rare diseases and orphan drugs
5.2.1.4 High cost of in-house drug development
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulations governing drug discovery and animal usage
5.2.3 OPPORTUNITIES
5.2.3.1 Growth in drugs and biologics market despite COVID-19 pandemic
5.2.3.2 Rising demand for specialized testing services among end users
5.2.3.3 Patent expiry
5.2.3.4 High growth prospects in emerging markets
5.2.4 CHALLENGES
5.2.4.1 Shortage of skilled personnel
5.2.5 MARKET TRENDS
5.2.5.1 Shift in drug discovery services due to growing adoption of AI-based tools
5.2.5.2 Increased outsourcing to emerging Asian economies
5.2.5.3 CRO industry consolidation
5.2.5.4 Integrated end-to-end R&D service solution
5.3 IMPACT OF COVID-19 ON THE DRUG DISCOVERY SERVICES MARKET
5.3.1 ASSUMPTIONS – DRUG DISCOVERY SERVICES MARKET ESTIMATION AND FORECAST
5.3.2 ASSUMPTIONS – COMPANY REVENUE GROWTH
5.4 RANGES/SCENARIO
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 TECHNOLOGY ANALYSIS
5.9 REGULATORY ANALYSIS
5.10 PORTER’S FIVE FORCES ANALYSIS
5.10.1 THREAT OF NEW ENTRANTS
5.10.2 THREAT OF SUBSTITUTES
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 BARGAINING POWER OF SUPPLIERS
5.10.5 DEGREE OF COMPETITION
6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS (Page No. - 74)
6.1 INTRODUCTION
6.2 TARGET SELECTION
6.2.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT THE GROWTH OF THIS MARKET
6.3 TARGET VALIDATION
6.3.1 RISING NUMBER OF DRUG DISCOVERY RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
6.4 HIT-TO-LEAD IDENTIFICATION
6.4.1 HIT-TO-LEAD IDENTIFICATION IS THE LARGEST PROCESS SEGMENT IN THE MARKET
6.5 LEAD OPTIMIZATION
6.5.1 LEAD OPTIMIZATION REQUIRES STATE-OF-THE-ART INFORMATICS SYSTEMS TO FACILITATE TRANSPARENT PRESENTATION AND ANALYSIS
6.6 CANDIDATE VALIDATION
6.6.1 FUTURE MANUFACTURING SUITABILITY, SCALE-UP, COMMERCIAL VIABILITY, AND COST-EFFECTIVENESS OF CANDIDATES HEAVILY IMPACT THE LONG-TERM SUCCESS OF DRUGS
7 DRUG DISCOVERY SERVICES MARKET, BY TYPE (Page No. - 88)
7.1 INTRODUCTION
7.2 CHEMISTRY SERVICES
7.2.1 GROWING CHEMICAL & BIOCHEMICAL TESTS AND WIDE APPLICATIONS OF CHEMISTRY IN DRUG DISCOVERY ARE MAJOR FACTORS DRIVING MARKET GROWTH
7.3 BIOLOGY SERVICES
7.3.1 THE INTRODUCTION OF GENOMICS AND PROTEOMICS WILL ENHANCE MARKET GROWTH
8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE (Page No. - 94)
8.1 INTRODUCTION
8.2 SMALL-MOLECULE DRUGS
8.2.1 INCREASING NUMBER OF START-UPS AND NEW ENTRANTS IN THE SMALL-MOLECULE DRUGS SEGMENT WILL DRIVE THE GROWTH OF THIS MARKET
8.3 BIOLOGIC DRUGS
8.3.1 SAFETY AND MANUFACTURING CHALLENGES ASSOCIATED WITH BIOLOGICS DEVELOPMENT TO DRIVE ADOPTION OF OUTSOURCING SERVICES
9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA (Page No. - 101)
9.1 INTRODUCTION
9.2 ONCOLOGY
9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH
9.3 INFECTIOUS & IMMUNE SYSTEM DISEASES
9.3.1 EPIDEMIC OUTBREAKS NECESSITATE INCREASING DRUG DISCOVERY ACTIVITIES
9.4 NEUROLOGY
9.4.1 THE INCREASING NUMBER OF PATIENTS SUFFERING FROM NEUROLOGICAL DISORDERS IS DRIVING MARKET GROWTH
9.5 DIGESTIVE SYSTEM DISEASES
9.5.1 LARGE POPULATION SEEKING EFFECTIVE REMEDIES FOR DIGESTIVE DISEASES IS EXPECTED TO DRIVE THE MARKET
9.6 CARDIOVASCULAR DISEASES
9.6.1 THE HIGH GLOBAL BURDEN OF CARDIOVASCULAR DISEASES HAS INCREASED THE FOCUS ON DEVELOPING EFFECTIVE DRUGS
9.7 OTHER THERAPEUTIC AREAS
10 DRUG DISCOVERY SERVICES MARKET, BY END USER (Page No. - 119)
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE
10.2.2 TIER 1 COMPANIES
10.2.2.1 High investing capacity is the major factor driving the growth of this segment
10.2.3 TIER 2 COMPANIES
10.2.3.1 Limited investment capacity is expected to restrain the growth of this segment
10.2.4 TIER 3 COMPANIES
10.2.4.1 Tier 3 companies are smaller and have fewer technical advantages
10.3 ACADEMIC INSTITUTES
10.3.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT
10.4 OTHER END USERS
11 DRUG DISCOVERY SERVICES MARKET, BY REGION (Page No. - 131)
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 US
11.2.1.1 Availability of advanced R&D infrastructure has driven the growth of the US market
11.2.2 CANADA
11.2.2.1 Preference of pharmaceutical companies to conduct clinical trials in Canada to support market growth
11.3 EUROPE
11.3.1 GERMANY
11.3.1.1 Government support and flexible labor laws are driving the growth of the German drug discovery services market
11.3.2 UK
11.3.2.1 Collaborations between the government and private stakeholders to support market growth
11.3.3 FRANCE
11.3.3.1 The high number of oncology research projects in France to drive market growth
11.3.4 ITALY
11.3.4.1 High number of clinical trials and the low drug approval time are the major factors driving market growth
11.3.5 SPAIN
11.3.5.1 Short study start-up times and rising R&D expenditure to boost the growth of the Spanish market
11.3.6 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 CHINA
11.4.1.1 China dominates the Asia Pacific market due to a robust pharmaceutical industry and the presence of prominent CROs
11.4.2 JAPAN
11.4.2.1 Government initiatives for drug innovation to support market growth in Japan
11.4.3 INDIA
11.4.3.1 Low-cost services and availability of skilled workforce and strong government support to drive market growth in India
11.4.4 SOUTH KOREA
11.4.4.1 Government initiatives and growing R&D activities for drug development to drive market growth
11.4.5 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 BRAZIL
11.5.1.1 The presence of a large pool of treatment-naïve patients and short approval timeline is expected to drive market growth in this region
11.5.2 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH IN THE MIDDLE EAST AND AFRICA
12 COMPETITIVE LANDSCAPE (Page No. - 183)
12.1 OVERVIEW
12.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
12.3 MARKET SHARE ANALYSIS
12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
12.5 COMPANY EVALUATION QUADRANT
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
12.7 COMPANY SERVICE FOOTPRINT
12.8 COMPANY GEOGRAPHIC FOOTPRINT
12.9 COMPETITIVE SCENARIO
12.9.1 SERVICE LAUNCHES
12.9.2 DEALS
12.9.3 EXPANSION
13 COMPANY PROFILES (Page No. - 196)
13.1 KEY PLAYERS
13.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS
13.1.1.1 Business overview
13.1.1.2 Services offered
13.1.1.3 Recent developments
13.1.1.4 MnM view
13.1.1.4.1 Key strengths/Right to win
13.1.1.4.2 Strategic choices made
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
13.1.2.1 Business overview
13.1.2.2 Services offered
13.1.2.3 Recent developments
13.1.2.4 MnM view
13.1.2.4.1 Key strengths/Right to win
13.1.2.4.2 Strategic choices made
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 WUXI APPTEC
13.1.3.1 Business overview
13.1.3.2 Services offered
13.1.3.3 Recent developments
13.1.3.4 MnM view
13.1.3.4.1 Key strengths/Right to win
13.1.3.4.2 Strategic choices made
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 THERMO FISHER SCIENTIFIC
13.1.4.1 Business overview
13.1.4.2 Services offered
13.1.4.3 Recent developments
13.1.5 PHARMARON BEIJING CO., LTD.
13.1.5.1 Business overview
13.1.5.2 Services offered
13.1.5.3 Recent developments
13.1.6 EVOTEC SE
13.1.6.1 Business overview
13.1.6.2 Services offered
13.1.6.3 Recent developments
13.1.7 EUROFINS SCIENTIFIC SE
13.1.7.1 Business overview
13.1.7.2 Services offered
13.1.7.3 Recent developments
13.1.8 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
13.1.8.1 Business overview
13.1.8.2 Services offered
13.1.9 PIRAMAL ENTERPRISES LIMITED
13.1.9.1 Business overview
13.1.9.2 Services offered
13.1.9.3 Recent developments
13.1.10 SYNGENE INTERNATIONAL LIMITED
13.1.10.1 Business overview
13.1.10.2 Services offered
13.1.10.3 Recent developments
13.1.11 CURIA GLOBAL INC.
13.1.11.1 Business overview
13.1.11.2 Services offered
13.1.11.3 Recent developments
13.1.12 GENSCRIPT BIOTECH CORPORATION
13.1.12.1 Business overview
13.1.12.2 Services offered
13.1.12.3 Recent developments
13.1.13 JUBILANT PHARMOVA LIMITED
13.1.13.1 Business overview
13.1.13.2 Services offered
13.1.13.3 Recent developments
13.1.14 FRONTAGE HOLDINGS CORPORATION
13.1.14.1 Business overview
13.1.14.2 Services offered
13.1.14.3 Recent developments
13.1.15 SHANGHAI MEDICILON INC.
13.1.15.1 Business overview
13.1.15.2 Services offered
13.1.15.3 Recent developments
13.1.16 DR. REDDY’S LABORATORIES LTD. (AURIGENE DISCOVERY TECHNOLOGIES)
13.1.16.1 Business overview
13.1.16.2 Services offered
13.1.16.3 Recent developments
13.2 OTHER COMPANIES
13.2.1 SELVITA S.A. (FORMERLY SELVITA CRO S.A.)
13.2.2 VIVA BIOTECH (SHANGHAI) LTD.
13.2.3 TCG LIFESCIENCES PVT LTD.
13.2.4 SHANGHAI CHEMPARTNER CO., LTD.
13.2.5 DOMAINEX LTD.
13.2.6 NUVISAN PHARMA HOLDING GMBH
13.2.7 DALTON PHARMA SERVICES
13.2.8 ARAGEN LIFE SCIENCES PVT. LTD. (FORMERLY GVK BIOSCIENCES PVT. LTD.)
13.2.9 PROMEGA CORPORATION
14 APPENDIX (Page No. - 274)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORT
14.5 AUTHOR DETAILS
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers